BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (AMEX: AKN) today announced that it has signed an Exclusive Supply Agreement with PrimaPharm, Inc., a privately-held pharmaceutical company located in San Diego, California to supply Hydase, a branded, NDA drug product indicated as an adjuvant to increase the absorption and dispersion of other injected drugs. The total United States market size for Hyaluronidase Injection is $8.6M, according to 2006 IMS data.
